Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference9 articles.
1. Centers for Medicare & Medicaid Services. NCA - monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease (CAG-00460N) - decision memo. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305 Accessed 12 Oct 2022.
2. Zeitler EP, Gilstrap LG, Coylewright M, Slotwiner DJ, Colla CH, Al-Khatib SM. Coverage with evidence development: where are we now? Am J Manag Care. 2022;28(8):382–9.
3. Foster NL, Mottola K, Hoffman JM. Coverage with evidence development: what to consider. JAMA Neurol. 2014;71(4):399–400.
4. Stern AM, Selkoe DJ. Unfairness to patients with Alzheimer disease in Medicare’s coverage of antiamyloid immunotherapy. JAMA Neurol. 2022;79(10):962–3.
5. Morin P, Li M, Wang Y, et al. Clinical staging of Alzheimer’s disease: concordance of subjective and objective assessments in the Veteran’s Affairs healthcare system. Neurol Ther. 2022;11(3):1341–52.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献